Articles related to REGULATORY AFFAIRS

Telehealth barriers include legal and regulatory issues at state and federal levels, with widespread adoption hampered by licensing portability challenges and reimbursement limitations.

FDA officials emphasize that unlike other high-income nations targeting elderly and high-risk populations, the US previously maintained universal vaccination recommendations for all Americans over 6 months, a policy they now consider insufficiently evidence-based.

Company leadership demands FDA explanation for approving identical treatment in patients with CIS while refusing filing for those without CIS, despite same trial data showing comparable clinical benefits and safety profiles.

Patients report significant weight loss with compounded semaglutide that would be difficult to maintain if forced to discontinue treatment due to cost barriers, despite manufacturer discount programs reducing brand-name medication costs to approximately $499 monthly.

Manufacturing deficiencies included inadequate contamination prevention and quality control measures, with historical context of previous recalls from the same facility that were associated with patient adverse events.

“…three drugs were associated with more negative or failed efficacy trials than positive ones…”